You just read:

Sun Pharma to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoriasis

News provided by

Sun Pharma

Oct 01, 2016, 05:05 ET